Biopharmaceutical Research Company (BRC) is a DEA-registered botanical cannabis firm focused on the federally compliant production of active pharmaceutical ingredients and partnered development and research. Led by CEO George Hodgin and based in Monterey, CA, the company holds an active Drug Enforcement Administration pharmaceutical cannabis license. BRC has engaged in partnered research with academic institutions including Washington State University and the University of California–Davis. The company raised $20M in a Series A to support its growth. BRC plans to use the funds to scale up operations, increase its product offering, conduct sponsored research, and execute its go-to-market strategy.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2022